Viking Therapeutics因计划发行股票和可转换债券而股价下跌

路透中文
Sep 24
BUZZ-<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a>因计划发行股票和可转换债券而股价下跌

9月23日 - ** 维京治疗公司(Viking Therapeutics, VKTX.O)股价在盘后交易中下跌8%,报38.32美元,该公司正寻求筹集资金

** VKTX (link) 宣布公开发行2亿美元股票及2亿美元可转换债券,该债券将于2032年10月15日到期

** 周二,VKTX股价飙升约36%至40.85美元,此前该公司用于治疗肥胖症的药物VK2735在一项研究中显示,与安慰剂组相比,患者体重减轻效果持久 (link)

** 公司计划将此次发行所得净收益用于VK2735项目的临床开发、推进及商业化,以及VK3019项目的推进等用途

** 摩根士丹利和摩根大通担任这两次发行的联合簿记管理人

** 周三,VKTX股价再涨2%,收于41.65美元

** 这家总部位于加利福尼亚州圣地亚哥的公司,基于约1.1665亿股流通股,市值约为49亿美元

** 据伦敦证券交易所集团(LSEG)数据显示,20位分析师的平均评级为“买入”,目标价中位数为100美元

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10